From Yahoo Finance: 2025-05-07 10:01:00

Truist analyst Joon Lee lowers Corcept Therapeutics (CORT) price target to $135 from $150, citing Q1 revenue softer than expected at $157.2M due to pharmacy vendor issues. Concerns arise if demand for relacorilant, a potential larger product, can be met by December 30 PDUFA approval. Analyst maintains Buy rating.

Read more: Corcept Therapeutics price target lowered to $135 from $150 at Truist